Misplaced Pages

Sepetaprost

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Sepetaprost
Clinical data
Other namesSTN-1012600
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • propan-2-yl 4--7-hydroxy-3,4,5,5a,6,7,8,8a-octahydro-2H-cyclopentaoxepin-3-yl]butanoate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC26H36F2O6
Molar mass482.565 g·mol
3D model (JSmol)
SMILES
  • CC(C)OC(=O)CCC1CC2(C(2/C=C/(COC3=C(C=CC(=C3)F)F)O)O)OC1
InChI
  • InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1
  • Key:BKVUSNOUTQMSBE-XCMGCKIWSA-N

Sepetaprost is an investigational new drug that is being evaluated for the treatment of open angle glaucoma and ocular hypertension. It is an agonist of the prostaglandin EP3 and F receptors.

References

  1. "Sepetaprost - Santen Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  2. Sharif NA, Odani-Kawabata N, Lu F, Pinchuk L (April 2023). "FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma". Experimental Eye Research. 229: 109415. doi:10.1016/j.exer.2023.109415. PMID 36803996.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: